JP2022153399A5 - - Google Patents

Download PDF

Info

Publication number
JP2022153399A5
JP2022153399A5 JP2022107704A JP2022107704A JP2022153399A5 JP 2022153399 A5 JP2022153399 A5 JP 2022153399A5 JP 2022107704 A JP2022107704 A JP 2022107704A JP 2022107704 A JP2022107704 A JP 2022107704A JP 2022153399 A5 JP2022153399 A5 JP 2022153399A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
tcr
acid residues
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022107704A
Other languages
English (en)
Japanese (ja)
Other versions
JP7437452B2 (ja
JP2022153399A (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/058576 external-priority patent/WO2017174822A1/en
Application filed filed Critical
Publication of JP2022153399A publication Critical patent/JP2022153399A/ja
Publication of JP2022153399A5 publication Critical patent/JP2022153399A5/ja
Application granted granted Critical
Publication of JP7437452B2 publication Critical patent/JP7437452B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022107704A 2016-04-08 2022-07-04 T細胞受容体 Active JP7437452B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201606172 2016-04-08
GB1606172.3 2016-04-08
PCT/EP2017/058576 WO2017174822A1 (en) 2016-04-08 2017-04-10 T cell receptors
JP2018552696A JP7179616B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018552696A Division JP7179616B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Publications (3)

Publication Number Publication Date
JP2022153399A JP2022153399A (ja) 2022-10-12
JP2022153399A5 true JP2022153399A5 (cg-RX-API-DMAC7.html) 2023-04-11
JP7437452B2 JP7437452B2 (ja) 2024-02-22

Family

ID=58701591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552696A Expired - Fee Related JP7179616B2 (ja) 2016-04-08 2017-04-10 T細胞受容体
JP2022107704A Active JP7437452B2 (ja) 2016-04-08 2022-07-04 T細胞受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018552696A Expired - Fee Related JP7179616B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Country Status (16)

Country Link
US (2) US20190135892A1 (cg-RX-API-DMAC7.html)
EP (2) EP3440102B1 (cg-RX-API-DMAC7.html)
JP (2) JP7179616B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190059874A (cg-RX-API-DMAC7.html)
CN (2) CN117603339A (cg-RX-API-DMAC7.html)
AU (2) AU2017248120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070600A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020530A1 (cg-RX-API-DMAC7.html)
DK (1) DK3440102T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991142T3 (cg-RX-API-DMAC7.html)
IL (1) IL262146A (cg-RX-API-DMAC7.html)
MX (1) MX2018012265A (cg-RX-API-DMAC7.html)
RU (1) RU2018138836A (cg-RX-API-DMAC7.html)
SG (1) SG11201808709VA (cg-RX-API-DMAC7.html)
WO (1) WO2017174822A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806865B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MX2018012265A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
JP7528058B2 (ja) * 2018-09-14 2024-08-05 イマティクス バイオテクノロジーズ ゲーエムベーハー Tcrリガンドの高スループットペプチド-mhc親和性スクリーニングのための方法
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
USD998170S1 (en) * 2019-04-10 2023-09-05 Inveox Gmbh Sample container
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CN114555791B (zh) 2019-08-13 2026-07-14 伦敦国王学院 Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US20230190803A1 (en) * 2020-05-13 2023-06-22 Adaptimmune Limited Method of treatment of cancer or tumour
WO2021236638A1 (en) * 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022140321A2 (en) * 2020-12-22 2022-06-30 Amgen Inc. Mage-b2-specific t-cell receptors
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4750806A1 (en) 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Antigen binding proteins against mageb2
EP4750807A1 (en) 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
RU2355703C2 (ru) 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US10024868B2 (en) 2009-06-09 2018-07-17 Vaxon Biotech Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
MX2018012265A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체

Similar Documents

Publication Publication Date Title
JP2022122913A5 (cg-RX-API-DMAC7.html)
JP2023081949A5 (cg-RX-API-DMAC7.html)
JP2020127406A5 (cg-RX-API-DMAC7.html)
CN109476724B (zh) T细胞受体
CN110023330B (zh) T细胞受体
CN102803487B (zh) 癌抗原辅助肽
JP2022554395A5 (cg-RX-API-DMAC7.html)
JP2020198875A5 (cg-RX-API-DMAC7.html)
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
PE20190124A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer
AR088455A1 (es) Anticuerpos que antagonizan cd40l
JP2025105774A5 (cg-RX-API-DMAC7.html)
AR105817A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
HRP20190472T4 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2023522799A5 (cg-RX-API-DMAC7.html)
WO2014197821A1 (en) Homeodomain fusion proteins and uses thereof
EA012507B1 (ru) Высокоаффинные мелан-а т-клеточные рецепторы
JP2023524788A5 (cg-RX-API-DMAC7.html)
JP2023542900A5 (cg-RX-API-DMAC7.html)
WO2021078774A1 (en) Specific binding molecules
JP2021531834A5 (cg-RX-API-DMAC7.html)
PE20211499A1 (es) Peptidos restringidos por a 03 para el uso en la inmunoterapia contra el cancer y metodos relacionados
AR110857A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
JP2022502078A5 (cg-RX-API-DMAC7.html)
JP2021045150A5 (cg-RX-API-DMAC7.html)